Why Amgen Stock Is Down Today Despite Solid Q2 Results
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
By no means were Amgen’s (NASDAQ: AMGN) second-quarter numbers “bad.” Revenue for most of its core drugs was up year over year, and the slight earnings dip is the predictable result of rising expenses. The pharmaceutical company’s outlook remains optimistic as well.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1455323545-9132d19b253042298a5e50cebc341788.jpg "Credit Scams to Watch Out For")
:max_bytes(150000):strip_icc():format(jpeg)/InsuranceScorehowitworks-5a42f332494ec90036720943.jpg "What Credit Score Should You Have?")
:max_bytes(150000):strip_icc():format(jpeg)/documents3-2c9f0be43694417aa7a597ee195072f1.jpg "How Long Does an Item Appear on My Credit Report?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1190222745-b65de6b6c3b948d2a22db5d28c5b1fb8.jpg "Is My Credit Score Good Enough for a Mortgage?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1390654298-5468501d88fb4e7faca533096301f91c-10635296cf604385879a8a0cdb404622.jpg "Best Strategies for Your Roth 401(k)")